Press releases
- IDEAYA Biosciences, Inc. Reports First Quarter 2024 Financial Results and Provides Business Update
- IDEAYA Biosciences to Participate in Upcoming May 2024 Investor Relations Event
- IDEAYA Biosciences Announces Inducement Grants under Nasdaq Listing Rule 5635(c)(4)
- IDEAYA Biosciences Announces ASCO 2024 Oral Presentation for Darovasertib in Neoadjuvant Uveal Melanoma Phase 2 Investigator Sponsored Study
- IDEAYA Biosciences Announces Selection of Move-Forward Phase 2 Expansion Dose for IDE397 Monotherapy in MTAP-Deletion Squamous Non-Small Cell Lung Cancer
- IDEAYA Biosciences to Participate in Upcoming April 2024 Investor Relations Event
- IDEAYA Announces Clinical Collaboration to Evaluate IDE161 in Combination with KEYTRUDA® (pembrolizumab) in Patients with Endometrial Cancer
- IDEAYA Biosciences to Participate in Upcoming March 2024 Investor Relations Events
- IDEAYA Biosciences, Inc. Reports Fourth Quarter and Full-Year 2023 Financial Results and Provides Business Update
More ▼
Key statistics
On Tuesday, IDEAYA Biosciences Inc (30J:DUS) closed at 39.40, -2.48% below its post-IPO high of 40.40, set on Apr 12, 2024.
52-week range
Short selling activityProvided by S&P Global Market Intelligence
Open | 39.40 |
---|---|
High | 39.40 |
Low | 38.60 |
Bid | 39.20 |
Offer | 40.20 |
Previous close | 39.00 |
Average volume | 0.00 |
---|---|
Shares outstanding | 74.76m |
Free float | 73.92m |
P/E (TTM) | -- |
Market cap | 3.22bn USD |
EPS (TTM) | -1.96 USD |
Data delayed at least 15 minutes, as of May 07 2024 18:30 BST.
More ▼